NORTHAMPTON, MA / ACCESS Newswire / June 3, 2025 / By Guy Diedrich, Ph.DIn every corner of the globe, digital technology is becoming the bridge to opportunity, empowerment, and transformation. Cisco's ...

Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple ...

Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma.

Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing ...

Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; ...

Johnson & Johnson shows strong profitability and solid value, but faces growth uncertainty, legal risks, and pricing ...

ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven ...

Johnson & Johnson (J&J) has announced that a US Food and Drug Administration (FDA) panel of experts has recommended Darzalex ...